BPC-157 and TB-500 blended dosing: hype vs. actual evidence
Quick answer
Neither BPC-157 nor TB-500 has received FDA approval or completed Phase III human trials for musculoskeletal recovery or performance optimization, meaning all dosing figures in circulation, including those in this video, are derived from animal research and community convention rather than validated human pharmacokinetics. The creator's suggested regimens of 500 mcg daily BPC-157 and 1 to 2 mg TB-500 every other day reflect commonly repeated bodybuilding protocols with no peer-reviewed dose-ranging basis in humans. Patients interested in peptide therapy should consult a licensed provider who can contextualize the limited evidence and monitor for individual risk factors.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @bakkebuilt actually say?
The creator said he prefers buying BPC-157 and TB-500 separately so he can "dose them differently." For blended bottles, he recommended "500 micrograms of each one every single day." For separate dosing, he suggested 500 mcg of BPC-157 daily and TB-500 at "1 to 2 milligrams every other day or every third day." He framed the whole thing as personal preference, not medical advice.
That framing matters. He is not claiming to treat a condition or citing clinical evidence. He is describing a practical workaround for a product-format issue. That is a more honest setup than most peptide content on TikTok. But the specific numbers he throws out still deserve scrutiny, because 107,000 views means a lot of people are treating this as a dosing guide.
Does the science back this up?
Barely, and not in the way most viewers probably assume. Neither BPC-157 nor TB-500 (thymosin beta-4 or its fragment) has completed a randomized controlled trial in humans for the recovery or optimization purposes being discussed here. The evidence base is almost entirely preclinical.
BPC-157 has shown regenerative effects in rat models of tendon, muscle, and gut injury (Sikiric et al., 2018, Current Pharmaceutical Design). TB-500 research in humans is even thinner. A Phase II trial of thymosin beta-4 by RegeneRx Biopharmaceuticals examined wound healing and cardiac repair, but results were mixed and the compound never reached approval. The dosing figures the creator cites, 500 mcg daily for BPC-157 and 1 to 2 mg of TB-500 every other day, appear to come from bodybuilding community consensus, not published pharmacokinetic studies. There is no peer-reviewed dose-ranging study in humans that validates these numbers.
What did they get wrong (or right)?
He got the flexibility argument right. If you are going to use these peptides at all, having separate vials does give you independent control over each compound's frequency and amount. That is a straightforward logistics point, and it is accurate.
Where things get murkier is the implicit suggestion that the dosing figures he cites are meaningful. Saying TB-500 should run "every other day or every third day" implies a known half-life or pharmacodynamic rationale. For TB-500, no reliable human half-life data exists in the published literature. The creator does not acknowledge this gap, which leaves viewers with the impression that these are evidence-based protocols rather than gym-floor convention.
He also does not address the real issue with blended peptide vials: consistency. Compounded blended products require that both peptides remain stable in the same reconstituted solution, at the same pH, over the same storage window. That is not guaranteed, and no reference standard exists for compounded blended peptides in the way one exists for single-ingredient pharmaceutical products.
What should you actually know?
The honest summary is this: BPC-157 and TB-500 are research peptides without FDA approval for any indication. The dosing figures circulating in bodybuilding communities are not derived from human clinical trials. They are extrapolated from animal studies and shared anecdotally.
That does not automatically mean they are dangerous at the amounts described, but it does mean no one, including the creator, actually knows what the optimal human dose is. The RegeneRx thymosin beta-4 trials used doses in the range of 6 mg total per treatment course for wound healing, which is structurally different from the chronic daily or every-other-day regimens being described here (Bhatt et al., 2012, Journal of Cardiovascular Pharmacology).
If you are considering these compounds, that conversation belongs with a licensed clinician who can review your full health picture, not a TikTok preference breakdown. The creator's transparency about this being personal preference is appreciated, but it does not substitute for a clinical evaluation.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
BPC-157 access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For BPC-157 and TB-500 blended dosing: hype vs. actual evidence, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Multifunctionality and Possible Medical Application of the BPC 157 Peptide
Used to frame BPC-157 as an investigational peptide with mixed preclinical and limited human evidence.
PubMed
Gastric pentadecapeptide BPC 157 and its role in accelerating musculoskeletal soft tissue healing
Supports cautious tissue-repair context without presenting BPC-157 as an approved therapy.
PubMed
beta-Thymosins
Background source for thymosin biology and tissue-repair mechanisms.
PubMed
Thymosin beta 4 and the eye: the journey from bench to bedside
Shows how thymosin beta-4 evidence differs by route, tissue, and clinical application.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
BPC-157 should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this bpc-157 video claims cluster
Best for searchers trying to separate BPC-157 research signals from overconfident recovery claims.
Claim verdict
The useful answer behind this video
Claim being checked
Neither BPC-157 nor TB-500 has received FDA approval or completed Phase III human trials for musculoskeletal recovery or performance optimization, meaning all dosing figures in circulation, including those in this video, are derived from animal research and community convention rather than validated human pharmacokinetics.
FormBlends verdict
Neither BPC-157 nor TB-500 has received FDA approval or completed Phase III human trials for musculoskeletal recovery or performance optimization, meaning all dosing figures in circulation, including those in this video, are derived from animal research and community convention rather than validated human pharmacokinetics. The creator's suggested regimens of 500 mcg daily BPC-157 and 1 to 2 mg TB-500 every other day reflect commonly repeated bodybuilding protocols with no peer-reviewed dose-ranging basis in humans. Patients interested in peptide therapy should consult a licensed provider who can contextualize the limited evidence and monitor for individual risk factors.
Patient-safe next step
Compare the claim with the BPC-157 guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Neither BPC-157 nor TB-500 has received FDA approval or completed Phase III human trials for musculoskeletal recovery or performance optimization, meaning all dosing figures in circulation, including those in this video, are derived from animal research and community convention rather than validated human pharmacokinetics. The creator's suggested regimens of 500 mcg daily BPC-157 and 1 to 2 mg TB-500 every other day reflect commonly repeated bodybuilding protocols with no peer-reviewed dose-ranging basis in humans. Patients interested in peptide therapy should consult a licensed provider who can contextualize the limited evidence and monitor for individual risk factors.
- Neither BPC-157 nor TB-500 has FDA approval for any indication, and neither has completed a Phase III randomized controlled trial in humans.
- The 500 mcg daily BPC-157 figure and the 1 to 2 mg TB-500 every-other-day figure are bodybuilding community conventions, not numbers from a published human pharmacokinetic study.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- BPC-157 decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the BPC-157 guide, cost path, safety notes, and provider review before acting.
Review BPC-157What You'll Learn
- Neither BPC-157 nor TB-500 has FDA approval for any indication, and neither has completed a Phase III randomized controlled trial in humans.
- The 500 mcg daily BPC-157 figure and the 1 to 2 mg TB-500 every-other-day figure are bodybuilding community conventions, not numbers from a published human pharmacokinetic study.
- RegeneRx's Phase II thymosin beta-4 trials (Bhatt et al., 2012) used episodic wound-healing dosing protocols that differ structurally from the chronic cycling described in this video.
- Preclinical BPC-157 research in rodents shows regenerative signals (Sikiric et al., 2018, Current Pharmaceutical Design), but animal-to-human dose extrapolation for peptides is not straightforward.
- Compounded blended peptide vials introduce stability variables that single-ingredient vials do not, since both compounds must remain intact in the same reconstituted solution over the same storage period.
- The creator's transparency about personal preference rather than clinical authority is a point in his favor, but 107,000 viewers are still likely treating these numbers as a validated protocol.
- Anyone considering BPC-157 or TB-500 should consult a licensed clinician before use, not use a TikTok video as a dosing reference.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Thomas Bakke · TikTok creator
107.1K views on this video
Replying to @G Poppa BPC 157 & TB 500 BLENDED DOSING ! Free Peptide Handbook Link in Bio #bpc #tb500 #peptide #peptidetherapy #bodybuilding
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Thomas Bakke, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.